TW202304963A - 標靶bcma的多特異性抗體 - Google Patents

標靶bcma的多特異性抗體 Download PDF

Info

Publication number
TW202304963A
TW202304963A TW111114188A TW111114188A TW202304963A TW 202304963 A TW202304963 A TW 202304963A TW 111114188 A TW111114188 A TW 111114188A TW 111114188 A TW111114188 A TW 111114188A TW 202304963 A TW202304963 A TW 202304963A
Authority
TW
Taiwan
Prior art keywords
seq
amino acid
acid sequence
antigen
sequence shown
Prior art date
Application number
TW111114188A
Other languages
English (en)
Chinese (zh)
Inventor
張兵
趙偉
陸亞敏
杜敏
甄子朋
謝美娟
汪鑫
席俊曉
宋馨
杜秀貞
Original Assignee
大陸商正大天晴藥業集團股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商正大天晴藥業集團股份有限公司 filed Critical 大陸商正大天晴藥業集團股份有限公司
Publication of TW202304963A publication Critical patent/TW202304963A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TW111114188A 2021-04-15 2022-04-14 標靶bcma的多特異性抗體 TW202304963A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110405638.3 2021-04-15
CN202110405638 2021-04-15

Publications (1)

Publication Number Publication Date
TW202304963A true TW202304963A (zh) 2023-02-01

Family

ID=83640152

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111114188A TW202304963A (zh) 2021-04-15 2022-04-14 標靶bcma的多特異性抗體

Country Status (12)

Country Link
US (1) US20240182592A1 (https=)
EP (1) EP4324853A4 (https=)
JP (1) JP2024516098A (https=)
KR (1) KR20230170721A (https=)
CN (1) CN117062840A (https=)
AU (1) AU2022256638A1 (https=)
BR (1) BR112023020341A2 (https=)
CA (1) CA3214012A1 (https=)
IL (1) IL307308A (https=)
MX (1) MX2023011923A (https=)
TW (1) TW202304963A (https=)
WO (1) WO2022218380A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12612635B2 (en) 2020-08-20 2026-04-28 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. BCMA-binding single variable structural domain and antigen-binding molecule
JP7821161B2 (ja) * 2020-08-20 2026-02-26 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド Ｂｃｍａと結合する単一可変ドメイン及び抗原結合分子
KR20260005269A (ko) * 2023-04-24 2026-01-09 치아타이 티안큉 파마수티컬 그룹 주식회사 c-Met를 표적으로 하는 다중 특이성 항체
CN119119246B (zh) * 2024-06-26 2025-10-10 中国农业科学院兰州兽医研究所(中国动物卫生与流行病学中心兰州分中心) 一种抗非洲猪瘟病毒k205r蛋白的纳米抗体及应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018028647A1 (en) 2016-08-10 2018-02-15 Legend Biotech Usa Inc. Chimeric antigen receptors targeting bcma and methods of use thereof
JP7267914B2 (ja) * 2016-11-02 2023-05-02 エンクマフ エスアーエールエル Ｂｃｍａ及びｃｄ３に対する二重特異性抗体、及び多発性骨髄腫を治療するために併用して使用される免疫療法薬
KR20250007003A (ko) * 2017-06-20 2025-01-13 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
WO2019195535A1 (en) 2018-04-05 2019-10-10 Novartis Ag Trispecific binding molecules against cancers and uses thereof
JP7410143B2 (ja) * 2018-11-01 2024-01-09 山▲東▼新▲時▼代▲薬▼▲業▼有限公司 二重特異性抗体及びその用途
CN110551221B (zh) * 2019-07-02 2021-03-05 广州爱思迈生物医药科技有限公司 一种双特异性抗体及其制备方法与应用
CN112574308A (zh) * 2019-09-30 2021-03-30 和铂医药(苏州)有限公司 靶向bcma的抗体、双特异性抗体及其用途
JP7821161B2 (ja) * 2020-08-20 2026-02-26 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド Ｂｃｍａと結合する単一可変ドメイン及び抗原結合分子
CN112794916B (zh) * 2021-04-08 2021-08-10 正大天晴药业集团南京顺欣制药有限公司 三特异性抗原结合构建体及构建方法和应用

Also Published As

Publication number Publication date
CN117062840A (zh) 2023-11-14
IL307308A (en) 2023-11-01
MX2023011923A (es) 2023-10-23
BR112023020341A2 (pt) 2024-02-06
AU2022256638A1 (en) 2023-11-09
WO2022218380A1 (zh) 2022-10-20
EP4324853A1 (en) 2024-02-21
JP2024516098A (ja) 2024-04-12
CA3214012A1 (en) 2022-10-20
EP4324853A4 (en) 2025-07-16
KR20230170721A (ko) 2023-12-19
US20240182592A1 (en) 2024-06-06

Similar Documents

Publication Publication Date Title
KR102944460B1 (ko) Cldn18.2 및 cd3에 대한 항체 작제물
TWI754800B (zh) 新型抗ox40/pd-l1雙特異性抗體分子、新型抗vegf/gitr雙特異性抗體分子及其用途
US9884921B2 (en) Bispecific heterodimeric diabodies and uses thereof
US20170327579A1 (en) Bispecific antibodies against cd3epsilon and bcma
TW202304963A (zh) 標靶bcma的多特異性抗體
JP2023550419A (ja) 二機能性分子
JP2024511642A (ja) 新規ｔｎｆｒ２結合分子
CN117940460A (zh) 双特异性抗原结合分子及其应用
TW202306984A (zh) 抗ｃｄ１３７抗體及使用方法
KR20230098334A (ko) Cldn6 및 cd3에 선택적으로 결합하는 폴리펩디드 작제물
CA3243623A1 (en) Immunoconjugated and its use
TW202307003A (zh) 抗ｃｅａ和抗ｃｄ１３７多特異性抗體及其使用方法
TWI894360B (zh) 抗tigit抗體及雙抗體和它們的應用
EA051272B1 (ru) Мультиспецифическое антитело, нацеленное на bcma
WO2023051680A1 (zh) 针对免疫检查点的双特异性抗体
TW202440645A (zh) 抗muc17*cd3*cd28三特異性抗體
WO2025157244A1 (zh) 抗b7h3抗体及其应用
WO2024160269A9 (zh) 针对muc17和cd3的双特异性抗体及其应用
CN116685606A (zh) 选择性地与cldn6和cd3结合的多肽构建体